AU697190B2 - IL8 inhibitors - Google Patents

IL8 inhibitors

Info

Publication number
AU697190B2
AU697190B2 AU78348/94A AU7834894A AU697190B2 AU 697190 B2 AU697190 B2 AU 697190B2 AU 78348/94 A AU78348/94 A AU 78348/94A AU 7834894 A AU7834894 A AU 7834894A AU 697190 B2 AU697190 B2 AU 697190B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
receptor
binding
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU78348/94A
Other languages
English (en)
Other versions
AU7834894A (en
Inventor
Guy Mullenbach
Patricia A Tekamp-Olson
Mary Ellen Wernette-Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU7834894A publication Critical patent/AU7834894A/en
Application granted granted Critical
Publication of AU697190B2 publication Critical patent/AU697190B2/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Request to Amend Deed and Register Assignors: CHIRON CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU78348/94A 1993-09-14 1994-09-13 IL8 inhibitors Ceased AU697190B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/121,105 US6448379B1 (en) 1993-09-14 1993-09-14 IL8 inhibitors
US121105 1993-09-14
PCT/US1994/010356 WO1995007934A2 (en) 1993-09-14 1994-09-13 Il8 inhibitors

Publications (2)

Publication Number Publication Date
AU7834894A AU7834894A (en) 1995-04-03
AU697190B2 true AU697190B2 (en) 1998-10-01

Family

ID=22394586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU78348/94A Ceased AU697190B2 (en) 1993-09-14 1994-09-13 IL8 inhibitors

Country Status (11)

Country Link
US (2) US6448379B1 (cg-RX-API-DMAC7.html)
EP (3) EP1283217B1 (cg-RX-API-DMAC7.html)
JP (3) JPH09502725A (cg-RX-API-DMAC7.html)
AT (2) ATE388168T1 (cg-RX-API-DMAC7.html)
AU (1) AU697190B2 (cg-RX-API-DMAC7.html)
CA (1) CA2171289C (cg-RX-API-DMAC7.html)
DE (2) DE69435083T2 (cg-RX-API-DMAC7.html)
DK (1) DK1283217T3 (cg-RX-API-DMAC7.html)
ES (1) ES2302774T3 (cg-RX-API-DMAC7.html)
PT (1) PT1283217E (cg-RX-API-DMAC7.html)
WO (1) WO1995007934A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6283896A (en) * 1995-06-20 1997-01-22 Chiron Corporation Interleukin-8 receptor binding compounds
AU777766B2 (en) * 1996-07-05 2004-10-28 Cancer Research Technology Limited Inhibitors of the interaction between p53 and MDM2
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP0939634A4 (en) * 1996-08-15 2001-02-21 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO1998046597A1 (en) * 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
ES2156534B1 (es) * 1999-02-03 2002-02-01 Smithkline Beecham Sa Nuevos inhibidores de la interaccion entre la interleuquina-8 y sus receptores
US20030186889A1 (en) * 2000-03-31 2003-10-02 Wolf-Georg Forssmann Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
NZ541050A (en) * 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2018067548A1 (en) 2016-10-03 2018-04-12 The Children's Medicial Center Corporation Prevention and treatment of diabetic nephropathy
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
JP2866182B2 (ja) 1990-10-08 1999-03-08 日本ケミファ株式会社 エンドセリン受容体
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5856457A (en) * 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
US5374506A (en) 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. OF IMMUNOLOGY VOL 150 NO 8 15 APRIL 1993 P126A *
SCIENCE VOL 253 13 SEPT. 1991 PP1278-1280 *

Also Published As

Publication number Publication date
WO1995007934A2 (en) 1995-03-23
CA2171289A1 (en) 1995-03-23
CA2171289C (en) 2007-04-10
EP1932856A2 (en) 2008-06-18
PT1283217E (pt) 2008-06-11
EP1283217B1 (en) 2008-03-05
DE69431843T2 (de) 2003-07-10
JP4122321B2 (ja) 2008-07-23
EP0719285A1 (en) 1996-07-03
EP0719285B1 (en) 2002-12-04
JPH09502725A (ja) 1997-03-18
DE69435083D1 (de) 2008-04-17
ATE229036T1 (de) 2002-12-15
US6436390B1 (en) 2002-08-20
JP2005023085A (ja) 2005-01-27
WO1995007934A3 (en) 1995-04-13
JP2008169227A (ja) 2008-07-24
DE69431843D1 (de) 2003-01-23
EP1932856A3 (en) 2009-09-30
ES2302774T3 (es) 2008-08-01
EP1283217A3 (en) 2003-09-17
EP1283217A2 (en) 2003-02-12
US6448379B1 (en) 2002-09-10
DK1283217T3 (da) 2008-07-07
AU7834894A (en) 1995-04-03
ATE388168T1 (de) 2008-03-15
DE69435083T2 (de) 2009-03-12

Similar Documents

Publication Publication Date Title
JP3675819B2 (ja) Ｃｄ４０に対する抗体
JP2008169227A (ja) Ｉｌ８阻害剤
KR100697120B1 (ko) Ｉｌ-18 매개 질환의 치료에 유용한 재조합 ｉｌ-18 길항제
US7101689B2 (en) Interleukin-18 binding proteins, their preparation and use
KR100496063B1 (ko) 신규단백질 및 그 제조방법
JP6140777B2 (ja) ヒトｉｌ−６受容体に対する高親和性抗体
US20060233792A1 (en) Train-R: a cysteine rich member of the TNF-receptor family
US20130059337A1 (en) Therapeutic Uses of Humanized Antibodies Against ALPHA-4 Integrin
CA2358693A1 (en) Anti-ccr4 antibodies and methods of use therefor
RU2126836C1 (ru) Моноклональное антитело к гликопротеину р человека
WO1999026977A1 (en) Novel receptors opg-2
WO1994012531A1 (en) Antagonists of human gamma interferon
KR20000016598A (ko) 신규단백질및그제조방법